Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - AVEO; GlaxoSmithKline; Novartis
Dmitry Nosov
No relevant relationships to disclose
Tim Eisen
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Pfizer; Roche
Stock Ownership - AstraZeneca
Honoraria - AVEO; Bayer; GlaxoSmithKline; Pfizer; Roche
Research Funding - AstraZeneca; Bayer; GlaxoSmithKline; Pfizer
Igor N. Bondarenko
No relevant relationships to disclose
Vladmir Lesovoy
No relevant relationships to disclose
Oleg N. Lipatov
No relevant relationships to disclose
Piotr Tomczak
No relevant relationships to disclose
Alexey A. Lyulko
No relevant relationships to disclose
Anna Alyasova
No relevant relationships to disclose
Mihai Harza
No relevant relationships to disclose
Mikhail Kogan
Research Funding - AVEO
Boris Y. Alexeev
Research Funding - AVEO
Cora N. Sternberg
Honoraria - Astellas Pharma
Cezary Szczylik
No relevant relationships to disclose
Joshua Zhang
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Andrew Louis Strahs
Employment or Leadership Position - AVEO (I)
Stock Ownership - AVEO
Brooke Esteves
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
William J. Slichenmyer
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Anna Berkenblit
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Thomas E. Hutson
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer